Asthma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Asthma Market Outlook

Thelansis’s “Asthma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Asthma   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Asthma Overview

Asthma represents a multifaceted clinical syndrome characterized by variable airflow obstruction, bronchial hyperresponsiveness (BHR), and cellular inflammation. The Global Initiative for Asthma (GINA) defines asthma as a heterogeneous disease primarily marked by airway inflammation. The presence of respiratory symptoms such as wheezing, shortness of breath, chest tightness, and cough, exhibiting variability over time and in intensity, alongside variable expiratory airflow limitation, constitutes the defining features of asthma. This condition results in fluctuating respiratory symptoms and variable airflow limitation, culminating in compromised activity levels, diminished quality of life, and occasional exacerbations, colloquially termed ‘asthma attacks.’ These exacerbations may necessitate emergency healthcare utilization and hospitalization and, in rare instances, lead to fatalities. Asthma’s risk factors encompass genetic, environmental, and host-related elements. While a family history of asthma is common, it is neither sufficient nor necessary for asthma development. Clinical categorization of asthma involves classifying it as mild intermittent, mild persistent, moderate persistent, or severe persistent based on symptom frequency, severity, and lung function assessed through forced expiratory volume in 1 second (FEV1). Asthma manifests in various types, including allergic asthma, aspirin-induced asthma, cough-variant asthma, exercise-induced asthma, nighttime asthma, steroid-resistant asthma, and occupational asthma. Asthma is frequently associated with comorbidities that can impact its clinical expression, with rhinitis, sinusitis, gastroesophageal reflux disease (GERD), obstructive sleep apnea (OSA), hormonal disorders, and psychopathologies reported as common contributing conditions. Although the specific influence of these comorbidities is yet to be fully characterized, their presence is noteworthy. Additionally, other conditions, sometimes unrelated to asthma, exhibit high prevalence among asthmatic patients. The pharmacological management of asthma involves several major drug classes, including bronchodilators (beta-2 agonists, anticholinergics), corticosteroids, leukotriene modifiers, mast cell stabilizers, methylxanthines, and immunomodulators. These drugs can be administered through inhalation, oral ingestion, or subcutaneous and intravenous injection, with inhaled forms available in aerosolized and powdered formulations.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Asthma  – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034